(Q44431627)

2 December 2017

Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves' disease (English)

1 reference

2 December 2017

Practical Treatment with Minimum Maintenance Dose of Anti-Thyroid Drugs for Prediction of Remission in Graves' Disease (English)

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.45

30 December 2023

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.45

30 December 2023

author name string

Taku Kashiwai

1

1 reference

2 December 2017

Yoh Hidaka

2

1 reference

2 December 2017

Toru Takano

3

1 reference

2 December 2017

Ke-ita Tatsumi

4

1 reference

2 December 2017

Yukiko Izumi

5

1 reference

2 December 2017

Yuki Shimaoka

6

1 reference

2 December 2017

Hisato Tada

7

1 reference

2 December 2017

Keiko Takeoka

8

1 reference

2 December 2017

Nobuyuki Amino

9

1 reference

2 December 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12733708

30 December 2023

publication date

1 February 2003

1 reference

2 December 2017

1 reference

2 December 2017

50

1 reference

2 December 2017

1

1 reference

2 December 2017

45-49

1 reference

Is there one successful antithyroid regimen for Graves' disease?

2 December 2017

1

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.45

30 December 2023

Hyperthyroidism

2

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.45

Thyrotropin-releasing hormone testing during antithyroid drug treatment of Graves' disease as an indicator of remission

30 December 2023

3

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.45

Plasma Free Triiodothyronine Response to Thyrotropin-Releasing Hormone to Predict the Remission of Graves’ Disease Treated with Antithyroid Drugs*

30 December 2023

4

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.45

Reappraisal of the 3,5,3'-triiodothyronine-suppression test in the prediction of long term outcome of antithyroid drug therapy in patients with hyperthyroid Graves' disease

30 December 2023

5

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.45

Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission

30 December 2023

6

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.45

Outcome of patients with Graves' disease after long-term medical treatment guided by triiodothyronine (T3) suppression test

30 December 2023

7

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.45

Thyroid hypoechogenic pattern at ultrasonography as a tool for predicting recurrence of hyperthyroidism after medical treatment in patients with Graves' disease

30 December 2023

8

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.45

Prediction of remission in Graves' disease treated with long-term carbimazole therapy: evaluation of technetium-99m thyroid uptake and TSH concentrations as prognostic indicators

30 December 2023

10

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.45

Serum Thyroglobulin Changes in Patients with Graves’ Disease Treated withLong Term Antithyroid Drug Therapy

30 December 2023

11

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.45

Serum triiodothyronine to thyroxine ratio: a newly recognized predictor of the outcome of hyperthyroidism due to Graves' disease

30 December 2023

12

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.45

Serum Free Triiodothyronine to Free Thyroxine Ratio Enables Early Prediction of the Outcome of Antithyroid Drug Therapy in Patients with Graves' Hyperthyroidism

30 December 2023

13

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.45

Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment

30 December 2023

14

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.45

Thionamide therapy in Graves' disease: relation of relapse rate to duration of therapy

30 December 2023

17

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.45

Antithyroid Drugs and Graves' Disease: A Prospective Randomized Evaluation of the Efficacy of Treatment Duration

30 December 2023

18

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.45

Antithyroid Drug Therapy for Graves' Hyperthyroidism: Is Long-Term Administration of a Small Maintenance Dose Necessary?

30 December 2023

19

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.45

Antithyroid drugs and Graves' disease - prospective randomized assessment of long-term treatment

30 December 2023

20

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.45

Long term antithyroid drug therapy for intractable cases of graves' disease

30 December 2023

21

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.45

Low response of the thyroid gland to endogenous thyrotropin increased by thyrotropin-releasing hormone in patients with euthyroid Graves' disease.

30 December 2023

22

1 reference

https://api.crossref.org/works/10.1507/ENDOCRJ.50.45

30 December 2023

Identifiers

1 reference

2 December 2017

1 reference